The peptide demonstrates remarkable stability in human gastric juice, remaining intact for more than 24 hours, which allows for effective oral administration in addition to systemic delivery routes
Immunogenicity: No Antibody Formation A critical safety consideration for any peptide therapy is immunogenicity, the potential to trigger immune system responses that could lead to allergic reactions, reduced efficacy through antibody neutralization, or autoimmune complications
But on the specific question of which has been more rigorously studied in humans, SS-31 clearly leads
Additionally, AVN-C has potent preventative effects in terms of hearing deterioration in C57BL/6 mice caused by kanamycin and furosemide in addition to protection of OHC from gentamicin-induced damage by reducing oxidative stress (Umugire et al
Syringe Units = Volume to Draw (mL) 100 = 0.4 mL 100 = 40 units Thymosin Alpha-1 Dosing Profile (10 mg Vial / 2.5 mL BAC Water) 0.8 mg Dose: Draw 20 units (0.2 mL)